Mylan Specialty Grants & Donations Portal

Mylan Specialty is committed to supporting educational initiatives that facilitate health care provider education, advance the quality of patient care, and align with Mylan Specialty's therapeutic and clinical interests. We also partner with charitable organizations that meet these criteria.

 Through our online application system, you and/or your organization can apply for the following:

  • CME or Non-CME Grants
  • EpiPen® (epinephrine) Auto-Injector Product Donations
  • Monetary Donation

If you would like to submit a request for an Investigator Initiated Trial (IIT) please click here.

Mylan Specialty L.P. will be accepting applications starting Monday, January 2, 2017 through Friday, April 28, 2017. The portal will re-open, Monday, July 2, 2017 through Friday, September 29, 2017. Mylan Specialty L.P. will be accepting educational initiatives for activities in the areas of interest listed below.

2017 Unrestricted Educational Grants Priority topics

Asthma/COPD, Allergy, Anaphylaxis and Multiple Sclerosis

Asthma and COPD

  • Generics in Respiratory
  • Combination treatment strategy in COPD, specifically LABA/LAMA
  • Triple Combination Therapy in Asthma and COPD
  • Role of ICS/LABA in COPD
  • Nebulization as a preferred maintenance therapy in COPD
  • Current and evolving COPD treatment strategy for discharge after acute exacerbations, the re-hospitalization, prevention and 30-day readmission
  • New devices/delivery systems
  • Asthma-COPD overlap syndrome (ACOS)
  • COPD: Special population (older, cognitively impaired, ethnic groups, dexterity, other)
  • Annual Respiratory conferences: scientific programs

Allergy/Allergic Rhinitis (AR)

  • Diagnosis and Treatment of AR
  • AR comorbidities (one airway, one disease), AR and Asthma
  • AR Guidelines
  • Biomarkers or other objective measures of rhinitis
  • Use in other indications (PAR, VAS, special populations)


  • Diagnosis of anaphylaxis
  • Treatment of anaphylaxis
  • Anaphylaxis Guidelines
  • Anaphylaxis demographics, incidence, prevalence

Multiple Sclerosis (Glatiramer Acetate)

  • Generics in MS
  • Therapeutic Management of RRMS
  • Disease-Modifying Therapy (DMT), focus on Safety
  • Annual MS conferences: scientific programs


  • Use of Biosimilars in Oncology
  • Use of Biosimilars in Diabetes
  • Use of Biosimilars in chemo-induced neutropenia
  • Regulatory pathway for FDA approval of Biosimilars